773TiPPRODIGE 51 - GASTFOX: Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric adenocarcinoma - Université Sorbonne Paris Nord Accéder directement au contenu
Communication Dans Un Congrès Année : 2017

773TiPPRODIGE 51 - GASTFOX: Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric adenocarcinoma

P. Artru
  • Fonction : Auteur
N. Baba-Hamed
  • Fonction : Auteur

Domaines

Cancer

Dates et versions

hal-01632489 , version 1 (10-11-2017)

Identifiants

Citer

A. Zaanan, E. Samalin, C. Louvet, C. Montérymard, F. Khemissa, et al.. 773TiPPRODIGE 51 - GASTFOX: Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric adenocarcinoma. the 42nd ESMO Congress (ESMO 2017), Sep 2017, Madrid, Spain. ⟨10.1093/annonc/mdx369.155⟩. ⟨hal-01632489⟩
151 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More